GO
Loading...

Dr.Reddy's Laboratories Ltd

  • Dec 5- A Massachusetts jury has found that an agreement between AstraZeneca Plc and Ranbaxy Laboratories Ltd to delay the launch of a generic version of AstraZeneca's heartburn drug Nexium was not anticompetitive. AstraZeneca and an attorney for Ranbaxy released statements saying they were pleased with the verdict. The lawsuit, which began in 2012,...

  • WASHINGTON, Nov 26- Switzerland's Novartis AG has agreed to sell its nicotine patch, Habitrol, in order to win U.S. antitrust approval for a consumer healthcare joint venture with Britain's GlaxoSmithKline, the U.S. Federal Trade Commission said on Wednesday. The deal is part of a three-way transaction unveiled in April, which includes GSK buying Novartis'...

  • Nov 20- A U.S. court has denied a request by Indian drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche's antiviral, a court filing showed. Ranbaxy had filed a lawsuit against the U.S. Food and Drug Administration last week for revoking tentative approvals it gave the company to make...

  • Nov 20- A U.S. court has denied a request by Indian drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche's antiviral Valcyte, a court filing showed. Ranbaxy had sought the restraining order against Dr Reddy's Laboratories and U.S. firm Endo International Plc in a lawsuit it filed...

  • *Ranbaxy says FDA revoked approval for copies of Nexium, Valcyte. *FDA said approvals were given "in error"- Ranbaxy. The FDA has also stripped Ranbaxy of tentative approval and six-month exclusivity for a copy of Roche Holding AG's antiviral Valcyte, a fresh blow to the Indian company that has been hit by a raft of regulatory bans over poor production quality.

  • Sept 15- Epirus Biopharmaceuticals Inc said India's drug regulator has approved its copy of a top-selling arthritis treatment, paving the way for its launch in the country early next year.

  • MUMBAI, Aug 29- Indian drugmakers are fleeing a regulatory morass at home and moving some research and development to Europe and the United States as try to boost margins by producing high-value drugs.

  • *Move aimed towards making drugs more affordable in India. MUMBAI, July 14- India has capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV, a move likely to hit the profit margins of drug firms such as Sanofi SA, Abbott Laboratories and Ranbaxy Laboratories Ltd..

  • Cramer: 50% gains in under 3 weeks?!! Thursday, 16 Jan 2014 | 6:42 PM ET

    January is a little more than half over and already these shares have gained almost 50% ytd. What's the story?

  • Futures Turn Higher on Tepper Remarks Tuesday, 14 May 2013 | 9:11 AM ET

    U.S. stock index futures signaled a lower open on Tuesday, as fears that China's central bank will not provide stimulus to boost its economy saw the Shanghai Composite fall to a one-week low.

  • Defective generic pill revives quality concerns Thursday, 4 Oct 2012 | 5:23 PM ET

    The Food and Drug Administration on Wednesday asked Teva Pharmaceuticals to withdraw its drug Budeprion XL 300 after testing showed the drug did not properly release its key ingredient.

  • Forget ETFs, Play Emerging Mkts Like This Thursday, 17 Feb 2011 | 5:40 PM ET

    With violence in the Middle East triggering a rotation out of emerging markets, how should you trade, especially if you still believe in the EM story?

  • Emerging Names You Don’t Know but Should Tuesday, 1 Feb 2011 | 6:09 PM ET

    Ron Shah Of Jina Ventures suggests putting money to work overseas in these 10 stocks.

  • 5 Ways to Invest in India Amid the Inflation Scare Tuesday, 11 Jan 2011 | 12:05 PM ET

    Indian stocks have been sliding since the New Year amid inflation fears but there are still places where investors can get in, said Ron Shah, managing partner at Jina Ventures.

  • Market Pro's Top 5 Plays on India Monday, 8 Nov 2010 | 7:02 PM ET

    With President Obama visiting the Subcontinent, Ron Shah of Jina Ventures recommends playing these Indian companies in the long-term.

  • Three Stock Picks to Boost Exposure to India Monday, 25 Oct 2010 | 1:59 PM ET
    India

    India's stock market has jumped almost 19% over the past year, far outpacing the Dow Jones Industrial Average, and it may not be done yet....A report from TheStreet.

  • Bet on Generics? Monday, 22 Feb 2010 | 5:46 PM ET

    With Barron’s turning very bullish on generic drugmaker Mylan Labs, should you put money to work in the generic space?

  • Follow The Money Into Emerging Markets? Friday, 23 Oct 2009 | 6:03 PM ET

    It seems new taxes on outside investors looking to play Brazil can’t dampen enthusiasm about emerging markets!

  • India Rising Monday, 18 May 2009 | 6:05 PM ET

    A decisive win by India's capitalism party over rival communists triggered the largest gains in stocks in about two decades. How should you be trading?

  • Indian Elections Boost Stocks Monday, 18 May 2009 | 9:47 AM ET

    Indian stocks that trade in the U.S. are up double digits as stock trading in India was halted for the first time because of a surge in stock prices on the big election victory for Prime Minister Singh's Congress Party.